Neurosciences bordeaux
Home page Search Researchers Students ITA Teams Platforms Labs FENS themes Program areas Publications fr - en
 
 
    
  Researcher:
 
Bezard
  Erwan Bezard
Researcher - PhD
CNRS ; Université de Bordeaux
cnrs
  Researcher
Lab Director - Neurodegenerative Diseases Institute
Team leader - Pathophysiology of parkinson's syndrome
Technological platform leader
Platform Biothèque primates
Address:
Institut des maladies neurodégénératives
CNRS UMR 5293
Université de Bordeaux
Bât 3B 1er étage
146 rue Léo Saignat

33076 Bordeaux cedex
Phone: +33 05 57 57 16 85
Fax: +33 05 56 90 14 21

Mail du chercheur: mail
tel: 33 (0)5 33 51 47 18
  Team:
Pathophysiology of parkinson's syndrome - Erwan Bezard  
 
  Program areas:
Normal and pathological motor control
Normal and pathological cognition
Neuropsychopharmacology and therapeutics of the deficiencies - transverse axis.


FENS Themes:
Neurological and psychiatric conditions / Neurodegenerative disorders ; Motor systems / Basal ganglia ; Synaptic transmission and excitability / G-protein linked receptors ; Cognition and behaviour / Animal cognition and behaviour

Scientific expertise:
movement disorders ; Parkinson's disease ; multiple system atrophy ; drug-induced dyskinesia ; animal models ; clinical expertise ; preclinical expertise ; drug development ; degenerative disease

Technical expertise:
molecular anatomy

Keywords:
Parkinson's disease ; dyskinesias ; dysregulation syndrome ; molecular anatomy ; dopamine ; behavior ; electrophysiology
   
   
 
Research projects: sing multidisciplinary approaches involving functional anatomy, biochemistry and molecular biology, we try to understand the mechanisms responsible for hypokinesia feature of parkinsonian syndromes, its response to L-Dopa and its complications such as dyskinesias Dopa-induced (DDI), as well as the mechanisms leading to neuronal death in these disorders. Our work involves analysis of the behavior and brain of rodents, non-human and human primate (human cérébrothèque) to establish correlations. Using mainly gene transfer or human brain-derived purified proteins, we then modulate the severity of symptoms or the degree of neuronal death in order to establish a causal link.
Publications: Clic here
   
   
     
 
  Conception et administration : C. Latié - © Développement web : Olivier Bertoncello Data Consulting